Kidney Diseases最新文献

{"title":"Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status.","authors":"Xingying Zhu, Wai W Cheung, Aihua Zhang, Guixia Ding","doi":"10.1159/000539516","DOIUrl":"10.1159/000539516","url":null,"abstract":"<p><strong>Background: </strong>Primary hyperoxaluria (PH) is a rare autosomal recessive disorder, mainly due to the increase in endogenous oxalate production, causing a series of clinical features such as kidney stones, nephrocalcinosis, progressive impairment of renal function, and systemic oxalosis. There are three common genetic causes of glycolate metabolism anomalies. Among them, PH type 1 is the most prevalent and severe type, and early end-stage renal failure often occurs.</p><p><strong>Summary: </strong>This review summarizes PH through pathophysiology, genotype, clinical manifestation, diagnosis, and treatment options. And explore the characteristics of Chinese PH patients.</p><p><strong>Key messages: </strong>Diagnosis of this rare disease is based on clinical symptoms, urinary or blood oxalate concentrations, liver biopsy, and genetic testing. Currently, the main treatment is massive hydration, citrate inhibition of crystallization, dialysis, liver and kidney transplantation, and pyridoxine. Recently, RNA interference drugs have also been used. In addition, technologies such as gene editing and autologous liver cell transplantation are also being developed. C.815_816insGA and c.33_34insC mutation in the <i>AGXT</i> gene could be a common variant in Chinese PH1 population. Mutations at the end of exon 6 account for approximately 50% of all Chinese HOGA1 mutations. Currently, the treatment of PH in China still relies mainly on symptomatic and high-throughput dialysis, with poor prognosis (especially for PH1 patients).</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"10 4","pages":"313-326"},"PeriodicalIF":3.2,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a Management Algorithm for Wet Contamination of Peritoneal Dialysis System on the Prevention of Peritonitis: A Prospective Observational Study.","authors":"Chunyan Yi, Wenbo Zhang, Qunying Guo, Jianxiong Lin, Wei Chen, Haiping Mao, Xiao Yang","doi":"10.1159/000539582","DOIUrl":"10.1159/000539582","url":null,"abstract":"<p><strong>Introduction: </strong>Wet contamination was a common problem of peritoneal dialysis (PD) system. We developed a management algorithm for wet contamination of PD system (wet contamination) on the basis of the related research literature and clinical practice experience. The purpose of this study was to observe clinical effect of the management algorithm on the prevention of peritonitis.</p><p><strong>Methods: </strong>Patients treated wet contamination in a single PD center between October 2017 and September 2022 were included. A management algorithm was established to treat wet contamination. It comprised identification of the contamination type, addressing contaminated or aging catheters, prophylactic antibiotics, and retraining. Demographic data and clinical data about wet contamination were collected and compared.</p><p><strong>Results: </strong>One hundred and forty-one cases of wet contamination were included in this study. The mean age was 51.7 ± 14.1 years, and 49.6% were female. The proportion of diabetic nephropathy was 9.9%. The median PD duration was 27.0 (1.7-79.7) months. Eighteen episodes (12.8%) of wet contamination-associated peritonitis developed after wet contamination. The main pathogenic bacteria of peritonitis were Gram-positive bacteria (33.3%) and Gram-negative bacteria (27.8%). The incidence of wet contamination-associated peritonitis in the compliance with the management algorithm group was significantly lower than that in the non-compliance with the management algorithm group (0.9 vs. 48.6%; <i>p</i> < 0.001). Non-compliance with management algorithm (OR = 185.861, <i>p</i> < 0.001) together with advance age (OR = 1.116, <i>p</i> < 0.001) and longer distance from home to hospital (OR = 1.007, <i>p</i> < 0.001) were independent risk factors for wet contamination-associated peritonitis.</p><p><strong>Conclusion: </strong>The management algorithm for wet contamination of PD system could reduce the risk of peritonitis.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"10 4","pages":"295-302"},"PeriodicalIF":3.2,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapy Targeted to the NLRP3 Inflammasome in Chronic Kidney Disease.","authors":"Yong Ji, Hu Hua, Zhanjun Jia, Aihua Zhang, Guixia Ding","doi":"10.1159/000539496","DOIUrl":"10.1159/000539496","url":null,"abstract":"<p><strong>Background: </strong>The NLRP3 inflammasome is a cytoplasmic polymeric protein complex composed of the cytoplasmic sensor NLRP3, the apoptosis-related spot-like protein ASC, and the inflammatory protease caspase-1. NLRP3 activates and releases IL-1β through classical pathways, and IL-18 mediates inflammation and activates gasdermin-D protein to induce cellular pyroptosis. Numerous studies have also emphasized the non-classical pathway activated by the NLRP3 inflammasome in chronic kidney disease (CKD) and the inflammasome-independent function of NLRP3.</p><p><strong>Summary: </strong>The NLRP3-targeting inflammasome and its associated pathways have thus been widely studied in models of CKD treatment, but no drug that targets NLRP3 has thus far been approved for the treatment of CKD.</p><p><strong>Key messages: </strong>We herein reviewed the current interventional methods for targeting the NLRP3 inflammasome in various CKD models, analyzed their underlying mechanisms of action, classified and compared them, and discussed the advantages and follow-up directions of various interventional methods. This review therefore provides novel ideas and a reference for the development of targeted NLRP3-inflammasome therapy in CKD.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"10 5","pages":"369-383"},"PeriodicalIF":3.2,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11488838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Extracellular Vesicle-Derived Noncoding RNAs in Diabetic Kidney Disease.","authors":"Miao Hu, Xiahong Shen, Ling Zhou","doi":"10.1159/000539024","DOIUrl":"10.1159/000539024","url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD), a metabolism-related syndrome characterized by abnormal glomerular filtration rate, proteinuria, and renal microangiopathy, is one of the most common forms of chronic kidney disease, whereas extracellular vesicles (EVs) have been recently evidenced as a novel cell communication player in DKD occurrence and progress via releasing various bioactive molecules, including proteins, lipids, and especially RNA, among which noncoding RNAs (including miRNAs, lncRNAs, and circRNAs) are the major regulators. However, the functional relevance of EV-derived ncRNAs in DKD is to be elucidated.</p><p><strong>Summary: </strong>Studies have reported that EV-derived ncRNAs regulate gene expression via a diverse range of regulatory mechanisms, contributing to diverse phenotypes related to DKD progression. Furthermore, there are already many potential clinical diagnostic and therapeutic studies based on these ncRNAs, which can be expected to have potential applications in clinical practice for EV-derived ncRNAs.</p><p><strong>Key messages: </strong>In the current review, we summarized the mechanistic role of EVs in DKD according to biological function classifications, including inflammation and oxidative stress, epithelial-mesenchymal transition, cell death, and extracellular matrix deposition. In addition, we comprehensively discussed the potential applications of EV-derived ncRNAs as diagnostic biomarkers and therapeutic targets in DKD.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"10 4","pages":"303-312"},"PeriodicalIF":3.2,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Arterial Calcification on Cardiovascular and Renal Outcomes in Kidney Transplant Patients.","authors":"Joohyung Ha, Jong Cheol Jeong, Jung-Hwa Ryu, Myung-Gyu Kim, Kyu Ha Huh, Kyo Won Lee, Hee-Yeon Jung, Kyung Pyo Kang, Han Ro, Seungyeup Han, Beom Seok Kim, Jaeseok Yang","doi":"10.1159/000538929","DOIUrl":"10.1159/000538929","url":null,"abstract":"<p><strong>Introduction: </strong>Coronary artery calcification score (CACS) and abdominal aortic calcification score (AACS) are both well-established markers of vascular stiffness, and previous studies have shown that a higher CACS is a risk factor for chronic kidney disease (CKD) progression. However, the impact of pretransplant CACS and AACS on cardiovascular and renal outcomes in kidney transplant patients has not been established.</p><p><strong>Methods: </strong>We included 944 kidney transplant recipients from the KoreaN cohort study for Outcome in patients With Kidney Transplantation (KNOW-KT) cohort and categorized them into three groups (low, medium, and high) according to baseline CACS (0, 0 < and ≤100, >100) and AACS (0, 1-4, >4). The low (0), medium (0 < and ≤ 100), and high (>100) CACS groups each consisted of 462, 213, and 225 patients, respectively. Similarly, the low (0), medium (1-4), and high (>4) AACS groups included 638, 159, and 147 patients, respectively. The primary outcome was the occurrence of cardiovascular events. The secondary outcomes were all-cause mortality and composite kidney outcomes, which comprised of >50% decline in the estimated glomerular filtration rate and graft loss. Cox regression analysis was used to investigate the association between baseline CACS/AACS and outcomes.</p><p><strong>Results: </strong>The high CACS group (<i>N</i> = 462) faced a significantly higher risk for cardiovascular outcomes (adjusted hazard ratio [aHR], 5.97; 95% confidence interval [CI], 2.01-17.7) and all-cause mortality (aHR, 2.74; 95% CI, 1.27-5.92) compared to the low CACS group (<i>N</i> = 225). Similarly, the high AACS group (<i>N</i> = 638) had an elevated risk for cardiovascular outcomes (aHR, 2.38; 95% CI, 1.16-4.88). Furthermore, the addition of CACS to prediction models improved prediction indices for cardiovascular outcomes. However, the risk of renal outcomes did not differ among CACS or AACS groups.</p><p><strong>Conclusion: </strong>Pretransplant arterial calcification, characterized by high CACS or AACS, is an independent risk factor for cardiovascular outcomes and mortality in kidney transplant patients.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"10 4","pages":"249-261"},"PeriodicalIF":3.2,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study.","authors":"Yan Tu, Zuo-Lin Li, Hong Liu, Ri-Ning Tang, Gui-Hua Wang, Lin-Li Lv, Bin Wang, Bi-Cheng Liu","doi":"10.1159/000538372","DOIUrl":"10.1159/000538372","url":null,"abstract":"<p><strong>Introduction: </strong>Roxadustat, the first-in-class drug for the treatment of renal anemia, has demonstrated efficacy in renal anemia with microinflammation. Additional data are needed regarding the efficacy of roxadustat on renal anemia with systemic macroinflammation.</p><p><strong>Methods: </strong>Three cohorts of renal anemia based on the basic level of high-sensitivity CRP were included. Patients with hsCRP ≤2 mg/L were selected as non-inflammation (NI) group; 2< hsCRP ≤10 mg/L as microinflammation (MI) group; hsCRP≥10 mg/L as macroinflammation (MA) group. Patients received oral roxadustat three times per week for 52 weeks. The primary end point was the hemoglobin level over weeks 12-52. The second end point was the cumulative proportion of patients achieving hemoglobin response by the end of week 12.</p><p><strong>Results: </strong>A total of 107 patients with chronic kidney diseases (CKDs) were enrolled. Overall, the baseline hemoglobin level of patients was 79.99 ± 11.20 g/L. Roxadustat could significantly increase the hemoglobin level in all of the three groups and did not show any significant difference (<i>p</i> > 0.05, respectively). Meanwhile, compared with that of the NI group, there was no significant difference in hemoglobin response rate in the MA group both at week 12 (<i>p</i> = 0.06; 95% confidence interval [CI], 0.9531-13.75) and week 52 (<i>p</i> = 0.37; 95% CI, 0.5080-7.937). Moreover, the hemoglobin response was independent of baseline hsCRP level (<i>p</i> = 0.72, 95% CI, -0.1139 to 0.0794). More importantly, roxadustat significantly reduced ferritin and serum iron levels and increased total iron-binding capacity in the three groups, which showed no significant differences among the three groups (<i>p</i> > 0.05, respectively).</p><p><strong>Conclusion: </strong>Roxadustat significantly improves anemia in CKD patients with systemic macroinflammation.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"10 3","pages":"193-199"},"PeriodicalIF":3.7,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Deep Insight into Ferroptosis in Renal Disease: Facts and Perspectives.","authors":"Zhongyu Han, Yuanke Luo, Haoran Chen, Guochen Zhang, Luling You, Meiqi Zhang, Yumeng Lin, Lan Yuan, Shiyi Zhou","doi":"10.1159/000538106","DOIUrl":"10.1159/000538106","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis, a newly recognized form of programmed cell death, is distinguished by its reliance on reactive oxygen species and iron-mediated lipid peroxidation, setting it apart from established types like apoptosis, cell necrosis, and autophagy. Recent studies suggest its role in exacerbating or mitigating diseases by influencing metabolic and signaling pathways in conditions such as tumors and ischemic organ damage. Evidence also links ferroptosis to various kidney diseases, prompting a review of its research status and potential breakthroughs in understanding and treating these conditions.</p><p><strong>Summary: </strong>In acute kidney disease (AKI), ferroptosis has been confirmed in animal kidneys after being induced by various factors such as renal ischemia-reperfusion and cisplatin, and glutathione peroxidase 4 (GPX4) is linked with AKI. Ferroptosis is associated with renal fibrosis in chronic kidney disease (CKD), TGF-β1 being crucial in this regard. In diabetic nephropathy (DN), high SLC7A11 and low nuclear receptor coactivator 4 (NCOA4) expressions are linked to disease progression. For polycystic kidney disease (PKD), ferroptosis promotes the disease by regulating ferroptosis in kidney tissue. Renal cell carcinoma (RCC) and lupus nephritis (LN) also have links to ferroptosis, with mtDNA and iron accumulation causing RCC and oxidative stress causing LN.</p><p><strong>Key messages: </strong>Ferroptosis is a newly identified form of programmed cell death that is associated with various diseases. It targets metabolic and signaling pathways and has been linked to kidney diseases such as AKI, CKD, PKD, DN, LN, and clear cell RCC. Understanding its role in these diseases could lead to breakthroughs in their pathogenesis, etiology, and treatment.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"10 3","pages":"224-236"},"PeriodicalIF":3.2,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141248057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T Cell Therapy: Advances in Kidney-Related Diseases","authors":"Longyuan Wu, Youqin Feng, Yue Huang, Jingjing Feng, Yong-xian Hu, He Huang","doi":"10.1159/000536194","DOIUrl":"https://doi.org/10.1159/000536194","url":null,"abstract":"Currently, renal malignancies and some diseases accompanied by renal impairment, such as multiple myeloma (MM), systemic lupus erythematosus (SLE), and acquired immunodeficiency syndrome (AIDS) are characterized by encouraging benefits from immunotherapy that have led to significantly improved outcomes. In this regard, the chimeric antigen receptor (CAR)-T represents a further step forward in the field of immunotherapy, which is becoming a hot issue and revealing potential in these diseases. Additionally, with numerous novel targets and indications being discovered and tried for clinical practice, the nephrotoxicity associated with CAR-T cell therapy also needs attention. In this review, we focused on discussing the effects and drawbacks of CAR-T cell therapy in several common diseases involving kidneys, as well as how we might enhance it.","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"62 24","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139441233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stabilizing hypoxia-inducible factor manage anemia in chronic kidney disease：From basic theory to clinical study","authors":"Yudian Wang, Xiaoyong Yu","doi":"10.1159/000536039","DOIUrl":"https://doi.org/10.1159/000536039","url":null,"abstract":"Background: Anemia is one of the common complications of chronic kidney disease (CKD), and its prevalence has been arising globally. The key cause of anemia in CKD patients is the diseased kidney's reduced ability to synthesize endogenous erythropoietin, yet this is not the sole reason. Inflammatory elements, functional iron deficiency, and uremic toxins together participate in the development of anemia. According to research data, anemia is an independent risk factor for cardiovascular events, all-cause mortality and worsening renal function, and affects the clinical prognosis and quality of life of CKD patients. Regular treatments for anemia in CKD patients include the use of erythropoietin stimulators (ESA), iron supplements, and blood transfusions. Summary：Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) is a novel and small molecule pharmacological compound that targets the HIF pathway and is another option for improving anemia in CKD patients. HIF-PHIs simulates hypoxia, stabilizes HIF protein, stimulates EPO synthesis, reduces hepcidin level and boosts iron utilization, induces the creation of red blood cells and alleviates anemia. The results of several HIF-PHIs phase III trials indicated that HIF-PHIs are similarly effective as ESA at raising hemoglobin (Hb) concentration. Key Messages: This article summarizes the structure of HIF and the mechanism of stabilizing HIF to improve anemia, discusses the efficacy of HIF-PHIs in CKD patients with or without dialysis, as well as emphasizes the potential safety concerns with HIF-PHIs.\u0000\u0000","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"42 24","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139451695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral Neuropathy Associated with Higher Mortality in Population with Chronic Kidney Disease: National Health and Nutrition Examination Surveys","authors":"Wei-Lan Li, X-Y Cai, Shu-Wang Ge, Gang Xu","doi":"10.1159/000535481","DOIUrl":"https://doi.org/10.1159/000535481","url":null,"abstract":"Background: Peripheral neuropathy (PN), one of the commonest neurological complications of chronic kidney disease (CKD), was associated with physical limitation. Studies showed that a decrease in physical capability in patients with CKD is related with an increased risk of mortality. The objective of our research is directly exploring the relationship between PN and risk of mortality in patients with CKD. Method: 1836 participants with CKD and 6036 participants without CKD, which were classified by peripheral neuropathy based on monofilament examination in National Health and Nutrition Examination Survey (NHANES), were collected from the 1999 to 2004 National Health and Nutrition Examination Surveys. Multi-variable Cox proportional hazards models was conducted to assess the relationships of peripheral neuropathy and deaths in patients with CKD and non-CKD. Results: During 14 years of a median follow up from 1999 to 2015 and 2004 to 2015, 1072 (58.4%) and 1389 (23.0%) deaths were recorded in participants with CKD and without CKD, respectively. PN was related with increased all-cause mortality even after adjusting possible confounding factors in population with CKD (HR 1.34, 95% confidence interval [CI] 1.17-1.53) and without CKD (HR 1.27 95% CI 1.12-1.43). And the adjusted HRs (95% CI) for cardiovascular mortality of the people with CKD and without CKD who suffering from peripheral neuropathy were 1.42 (1.07, 1.90) and 1.23 (0.91, 1.67), respectively, versus those without peripheral neuropathy. Conclusion: PN was related with a higher risk of all-cause and cardiovascular death in people with CKD, which clinically suggests that the adverse prognostic impact of PN in the CKD population deserve attention and are an important target for intervention.","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"2 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139163135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}